However, in contrast to the results in R/M HNSCC, alpelisib in combination with drugs targeting the estrogen receptors has shown robust responses compared to single-agent drugs, leading to the FDA approval of alpelisib for the treatment of PIK3CA-mutant metastatic breast cancer [60,61]. Here, PIK3CA is linked to head and neck squamous cell carcinoma.